Revolution Medicines Inc

NASDAQ:RVMDUnited States

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Contact Information

Headquarters

700 Saginaw DrREDWOOD CITY, CA, United States 94063-4752

Phone

415-766-3638

Fax

302-636-5454

Executives

Chairman of the Board, President, Chief Executive Officer

Mark Goldsmith

Chief Financial Officer

Jack Anders

President - Research and Development

Steve Kelsey

Chief Operating Officer

Margaret Horn

Executive Vice President - Clinical Development

Xiaolin Wang